PGM
CYCN icon

Parian Global Management’s Cyclerion Therapeutics CYCN Stock Holding History

Parian Global Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-875
Closed -$212K – 48
2019
Q3 		$212K Buy
+875
New +$189K 0.1% 29

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parian Global Management's CYCN Position: Q4 2019 in Review

Parian Global Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2019, closing a stake of 875 shares — an estimated $212K sold.

Parian Global Management first reported a position in CYCN in Q3 2019 and held it in 1 quarter. The position peaked at $212K in Q3 2019. 77 funds tracked by Wall St. Rank hold CYCN as of Q4 2019.

  • Parian Global Management reported no remaining Cyclerion Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Parian Global Management sold 875 Cyclerion Therapeutics shares in Q4 2019, an estimated $212K.
  • Parian Global Management first reported a position in Cyclerion Therapeutics in Q3 2019 and held it in 1 quarter.
  • Parian Global Management's Cyclerion Therapeutics position peaked at $212K in Q3 2019.
  • 77 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2019.

Based on Parian Global Management's 13F filing for Q4 2019, filed 14 Feb 2020.